- Home
- / Ascentage Pharma
Ascentage Pharma
Stock Price
$45.5
2024-10-29
Market Capitalization
$14 B
2024-10-29
Revenue
¥574.1 M
FY, 2025
Ascentage Pharma Summary
Company Summary
- Overview
- Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies. Its products include olverembatinib, lisaftoclax, etc.
- Type
- Public
- Status
- Active
- Founded
- 2017
- HQ
- Suzhou, CN | view all locations
- Website
- https://www.ascentage.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Zhai Yifan, Chief Medical Officer
Raymond Jeffrey Kmetz, Chief Business Officer
Thomas Joseph Knapp, Senior Vice President, General Counsel
LocationsView all
7 locations detected
Suzhou, Jiang Su Sheng HQ
China
68 Xinqing Road, Suzhou Industrial Park
Rockville, MD
United States
800 King Farm Blvd #300
Guangzhou Shi, Guangdong Sheng
China
2706, 403 Huanshi E Rd, Huan Shi Dong Lu Yan Xian, Yuexiu Qu
Suzhou Shi, Jiangsu Sheng
China
building b7, 7th floor, 218 Xinghu St, Wuzhong Qu
Taizhou
China
Hailing District
Beijing Shi
China
Ascentage Pharma Financials
Summary Financials
- Revenue (FY, 2025)
- ¥574.1M
- Gross profit (FY, 2025)
- ¥546.6M
- Net income (FY, 2025)
- (¥1.2B)
- Cash (FY, 2025)
- ¥2.5B
- EBIT (FY, 2025)
- (¥1.2B)
- Enterprise value
- $13.6B